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The  field  of  genomic  medicine  continues  to  expand, 
driven by the efforts of numerous researchers around the 
world. To celebrate Genome Medicine’s 2nd anniversary, 
we  asked  our  Section  Editors  what  they  felt  were  the 
most  exciting  breakthroughs  in  research  in  the  past 
2 years and what the future of genomic medicine might 
hold.
Transformational effect of systems medicine
Since  we  discussed  systems  medicine  as  the  future  of 
medical genomics and healthcare in the inaugural issue 
of Genome Medicine [1], the field has witnessed trans­
formational changes that have brought the prospect and 
promises of personalized medicine closer to reality. The 
exponential  increase  in  DNA  sequencing  capabilities, 
together with the rapidly declining associated costs, has 
made  whole­genome  sequencing  accessible  to  small 
labora  tories, and will soon transform it into a low cost 
analytical assay. These advances have enabled the emer­
gence of medical systems genetics studies, an approach in 
which the genetic determinants of diseases are investi­
gated  through  sequencing  of  the  complete  genome  of 
family relatives. For example, sequencing and analysis of 
the  genomes  of  two  siblings  and  their  parents  made 
possible the direct measurement of the inter­generational 
mutation rate and identified genes potentially associated 
with two Mendelian disorders [2]; the gene causing one 
of these disorders was precisely identified through further 
exome  sequencing  in  additional  diseased  patients  [3]. 
Another telling example of both the power and current 
limitations of the next­generation sequencing approaches 
is their application to the characterization of the genome, 
epigenome  and  transcriptome  of  monozygotic  twins 
discordant for multiple sclerosis, which failed to uncover 
significant  differences  associated  with  the  disease  [4]. 
With several thousand genomes now being completed, 
and tens of thousands anticipated in the coming year, the 
limitation is already to a large extent, and will increasingly 
be, on the side of data analysis, as the collection, storage 
and analysis of the large datasets generated requires the 
combined  expertise  of  a  wide  variety  of  scientists, 
engineers and physicians [5]. Fortunately, the software, 
databases  and  computing  power  required  for  these 
community efforts are now becoming available through 
computer  grids  and  cloud  computing  infrastructures, 
offering an affordable alternative for genome and trans­
lational bioinformatics [6,7]. Combined together, genome 
sequencing  and  cloud  computing  will  contribute  to 
bridging the gap between systems biology and medicine 
by opening the way to the precise and low cost assays that 
are necessary for systems medicine to become a practical 
alternative to traditional reactive medicine [8].
Charles Auffray, Section Editor,   
Systems medicine and informatics
The public perception challenge
Public perception research has long been a big part of the 
ethical,  legal  and  social  issues  (ELSI)  research  agenda. 
Over the past decades a wide range of methods have been 
deployed  to  tease  out  how  the  public  (whatever  that 
might be) feels about everything from gene patents to 
genetic privacy to the utility of direct­to­consumer test­
ing services. However, understanding public percep  tions 
has never been more important than it is now. Genomic 
research  requires  even  more  research  partici  pants, 
through such initiatives as large population bio  banking 
studies. And the clinical value of many proposed genomic 
interventions  depends  on  a  public  response  to  gene­
based risk information (such as the promotion of healthy 
lifestyle changes). Understanding how the public views 
and is likely to respond to genetic information will have 
an  impact  on  both  the  nature  of  research  that  can  be 
done and whether we will derive social benefit from that 
research. Recent public perception research has demon­
strated that the challenges in both of these areas could be 
profound. For example, a study that included 16 focus 
groups and a survey of over 4,000 individuals concluded 
that the public wants ongoing control over their genetic 
samples that have been donated for research [9]. Subse­
quent studies have come to similar results [10]. People 
want  ‘control.’  They  want  to  consent.  But  can  we  give 
mean  ing  to  this  public  desire  and  still  carry  out  big 
genomic studies? The research on how people respond to  © 2010 BioMed Central Ltd
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deflating, at least from a public health perspective. The 
emerging  data,  wonderfully  summarized  in  a  recent 
Cochrane Collaboration review [11], highlights that the 
public response to genetic risk information seems likely 
to be rather muted [12]. Given this reality, at least one 
aspect  of  the  long  promised  benefits  of  genomics­
informed personalized medicine ­ that is, the promotion 
of individualized preventive health strategies ­ may not 
pan out as expected. What is probably needed is both a 
more realistic appraisal of how genetic information will 
assist approaches to public health and more research into 
the ways in which genetic information can supplement, if 
at all, existing disease risk information.
Timothy Caulfield, Section Editor,   
Social, ethical and legal issues in genomic medicine
The translational gap in genomic medicine
Rapid advances in genomics and related technologies are 
promising  a  new  era  of  personalized  healthcare  and 
disease prevention, including new drugs, diagnostic and 
screening tests based on individual genetic makeup and 
disease  biomarkers.  Scientists  predict  that  the  age  of 
persona  lized  health  care  has  arrived.  Nevertheless,  the 
gap  is  still  wide  between  new  discoveries  and  their 
clinical validity and utility in practice [13]. The expansion 
of  direct­to­consumer  marketing  of  personal  genome 
profiles for risk assessment and disease prevention illus­
trates  the  premature  deployment  of  this  technology 
without the appropriate evidence base to support their 
use in practice [14]. If the promise of genomics is to be 
fulfilled,  we  must  use  scientific  methods  to  document 
how such technologies can improve health and prevent 
disease in practice. Dealing with the genomics evidence 
gap  will  require  two  key  and  interrelated  science  and 
policy areas, which are crucial to accelerating the appro­
priate translation of genomics into clinical practice. The 
first is to develop a multidisciplinary translation research 
agenda,  including  more  clinical  and  population­based 
research, in the life cycle of research from the bench to 
improved  population  health  outcomes  [15,16],  and  the 
second is to develop a stakeholder collaboration to effect 
evidence­based  translation.  Translation  research  is 
necessary, but not sufficient, to move specific genomic 
applications  from  research  into  practice.  Actual  trans­
lation  is  even  more  complicated.  Different  forces  can 
accelerate  or  impede  the  translation  process,  such  as 
private investments in research and development, policy 
and legal frameworks, oversight and regulation, product 
marketing,  coverage  and  reimbursements,  consumer 
advocacy, provider awareness, access, and health services 
development and implementation [17,18].
Muin Khoury, Section Editor,   
Genomic epidemiology and public health genomics
Genome Medicine and personal genomics
In order for the discipline of genomic medicine to fulfill 
its  maximum  potential  and  utility  in  the  clinic,  it  is 
necessary to be able to characterize all forms of genetic 
variation in an individual patient’s genome. This includes 
single  or  simple  nucleotide  variation  (SNV)  and  copy 
number variation (CNV). Personal genome sequencing is 
becoming a reality. The complete nucleotide sequence of 
James  Dewey  Watson,  55  years  after  his  discovery  of 
DNA and two decades after he led the human genome 
project,  provided  tremendous  insights  into  personal 
genomes. It was the first human genome sequenced by 
next generation sequencing [19] and revealed extensive 
variation:  greater  than  3  million  SNV  differences  in 
comparison with the reference haploid human genome 
sequence and a high frequency of small sized CNVs (less 
than 1 kb) that were beyond the detection limits of array 
comparative genomic hybridization. Another major find­
ing was the amount of Alu repetitive element polymorph­
isms  ­  indels  (insertions  or  deletions)  representing 
dimor  phisms of Alu at a particular locus. Thus, for each 
personal genome the amount of structural variation related 
to the position of repetitive elements could be immense. 
The  remarkable  extent  of  genome  structural  variation  in 
populations was further revealed by Conrad et al. [20].
The next important step in personal genomics was to 
use whole­genome sequence to associate specific varia­
tion with clinical disease phenotypes, and thus identify 
medically actionable variation from the myriad of benign 
polymorphic variations; that is, detect signal from noise. 
Whole­genome sequencing (WGS) was used to identify 
the cause of Charcot­Marie­Tooth neuropathy. Surpris  ingly, 
this  work  also  provided  insights  into  genetic  variation 
underlying common complex traits such as carpal tunnel 
syndrome  [21].  Whole  exome  sequencing  (WES)  has 
also  now  been  used  to  find  the  medically  actionable 
alleles  in  defined  clinical  Mendelian  phenotypes  for 
which the causative genes were unknown (for example, 
[3,22­24]),  and  to  make  a  definitive  diagnosis  for  a 
patient  with  a  complex  trait  [25].  Further  exome 
sequencing  work  recently  documented  that  new 
mutations  may  contribute  in  a  significant  way  to 
common  traits  such  as  mental  retardation  and 
intellectual disability [26]. This latter study emphasizes 
the importance of personal genomics for assessing not 
only inherited variation but also de novo events.
However,  we  must  not  lose  sight  of  the  challenges! 
Exome  sequencing  provides  essentially  no  information 
about  structural  variation  and  CNV.  Whole­genome 
sequenc  ing can provide structural variation information, 
but it is not obvious to what extent short read sequences 
can capture CNV, such as those of only a few hundred 
base pairs that may delete or duplicate single exons [27] 
or  delineate  complex  rearrangements,  given  the 
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reads to a haploid human reference genome. Whether or 
not WES or WGS will discern repeat expansion, a highly 
significant  form  of  pathology­associated  genetic 
variation, also remains to be demonstrated. Nevertheless, 
from  the  insights  already  provided,  it  is  clear  that  the 
information that can be gleaned from personal genome 
sequencing will probably be so compelling that clinicians 
will be motivated to rapidly adapt it into clinical practice.
James R Lupski, Section Editor,   
Molecular genetics, genomics and epigenetics of disease
The paradigm-shift of personalized medicine
The  modern  concept  of  personalized  medicine  is 
stimulated by the idea that genomic medicine may help 
to  prevent  and/or  treat  diseases  by  the  use  of  the 
individual genetic information of the host, tumor and/or 
other biological organisms (such as bacteria). Pharmaco­
genomics,  a  distinct  discipline  within  the  field  of 
personalized  medicine,  includes  the  study  of  the 
influence of genetic variation on drug response, but also 
comprises  the  genome­wide  and  multi­factorial  exten­
sion.  Thus,  in  the  modern  conception  of  personal  ized 
medicine, the tools that are provided to the physician are 
hopefully more precise, considering not just the obvious, 
such as a malign tumor by computer tomography, but the 
individual  genetic  make­up  of  the  patient.  There  are 
several examples in which a profile of a patient’s genetic 
variation  is  used  to  guide  the  selection  of  drugs  or 
treatment  processes,  leading  to  a  more  successful  out­
come from the medical treatment [28]. The question is 
no longer what if this could happen in clinical practice, 
but when. Consideration of new ‘omics­based biomarkers 
for patient stratification should by no means exclude the 
use  of  traditional  biomarkers,  such  as  a  patient’s  age, 
body composition, physical examination findings, blood 
pressure, and so on, for diagnosis of disease and choice of 
prevention  or  treatment.  However,  personalized  treat­
ment needs to combine clinical assessment and disease 
diagnostic tests with treatment­related (genetic) tests. In 
addition  to  biomarkers  predicting  the  efficacy  and,  if 
possible, effectiveness of a treatment, sufficient attention 
must also be given to the use of biomarkers for predicting 
drug safety. Considerable research activities in biomarker 
discovery and validation are ongoing, but little is being 
done to bring this information into clinical practice [29]. 
The  cost  of  sequencing  the  human  genome  falls  and 
whole­genome sequencing is already occurring, but data 
interpretation requires expertise not only related to the 
genetics of disease, but also related to pharmacological 
principles.  Continuing  Medical  Education  courses  on 
personalized  medicine,  particularly  with  focus  on 
genomic  issues,  need  to  be  made  available  to  bring 
physicians to the latest technological developments. To 
this end there is still a substantial need to demonstrate 
the  potential  added  value  that  personalized  genomic­
based approaches bring, in particular the added value of 
patient  stratification  in  view  of  improved  effectiveness 
and/or reduction of adverse side effects.
Matthias Schwab, Section Editor,   
Personalized medicine and therapeutics
From sensitive technologies to clinical action
Undoubtedly  the  greatest  advances  in  translational 
medicine over the past decade have been in the area of 
genetics. The advent of next­generation sequencing tech­
nologies have made genome­wide association studies, the 
identification  of  large  numbers  of  single  nucleotide 
polymorphisms and copy number variants that influence 
disease possible. In the post­genomic era, the hope is that 
advances in proteomic measurements can mimic those 
made  in  genetics.  Although  progress  has  not  been  as 
dramatic,  technologies  for  protein  measurements  are 
making  important  strides  in  translational  medicine.  If 
proteomic  technologies  are  to  have  an  impact  on 
translational medicine, however, they must be adaptable 
to  analyzing  clinic  samples.  This  requirement  means 
analyzing  small  volumes  of  biofluids  and  thin  tissue 
sections, both fresh frozen and formalin­fixed. One of the 
most important developments to achieving this goal is 
the  increasing  sensitivity  provided  by  mass  spectro­
meters. In the past highly sensitive mass spectrometers 
were  limited  to  specialized  mass  spectrometry  (MS) 
laboratories.  Nowadays,  instruments  that  routinely 
measure  sub­femtomole  levels  of  proteins  in  complex 
biological matrices are being widely used in traditionally 
non­MS laboratories. Thousands of proteins can now be 
identified  from  as  little  as  100  µl  of  blood  [30].  Laser 
capture  microdissection  of  approximately  5,000  cells 
from  thin  tissue  sections  can  now  provide  upwards  of 
2,500  confident  protein  identifications  [31].  With  the 
develop  ment  of  methods  to  extract  proteins  from 
formalin­fixed  tissue  sections,  MS  can  now  analyze  a 
seemingly inexhaustible source of tissues from countless 
tumor types [32]. The sensitivity provided by modern mass 
spectrometers  leads  to  greater  proteomic  coverage  for 
identifying disease­specific biomarkers and enhancing the 
quantitative measurement of specific proteins in clinical 
samples. Unfortunately, increased sensitivity com  pounds 
an existing problem specifically in the use of MS for the 
discovery of disease­specific biomarkers: turning data into 
information. The next big development in post­genomic 
medicine will be devising methods or bioinformatic tools 
to recognize potentially valuable protein biomarkers in the 
complex datasets generated using MS.
Timothy D Veenstra, Section Editor,   
Post-genomic advances in medicine
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